The clinical implications of new oral anticoagulants: will the potential advantages be achieved?
Phillips
Katherine W
KW
Department of Pharmacy, Boston Medical Center, Boston, Massachusetts, USA.
Ansell
Jack
J
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001777:Blood Coagulation / Q000187:drug effects*; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D065427:Factor Xa Inhibitors; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011516:Prothrombin / Q000037:antagonists & inhibitors; D018570:Risk Assessment; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014812:Vitamin K; D011516:Prothrombin; C025337:Factor IIa